Global tuberculosis drug development pipeline: the need and the reality
Global tuberculosis drug development pipeline: the need and the reality
复制标题
DOI：
10.1016/s0140-6736(10)60359-9
复制
发表时间：
2010-06-12
期刊：
影响因子：
168.9
通讯作者：
Wang, Xiexiu
中科院分区：
文献类型：
--
作者：
Ma, Zhenkun;Lienhardt, Christian;Wang, Xiexiu
治疗结核病的药物不足以应对许多固有的和新出现的治疗挑战。在过去的十年中，有10种化合物进入了临床开发流程，其中包括6种专门为结核病开发的新化合物。尽管取得了这一进展，但全球结核病药物管道仍然不足以满足未得到满足的治疗需求。需要更多和可持续的努力和资金来进一步改善这条管道。开发新疗法的关键挑战是需要新的药物组合、新的试验设计、在儿科人群中进行研究、增加临床试验能力、明确的监管指南以及预测长期结果的生物标记物。尽管在控制结核病的努力方面取得了实质性进展，但这种疾病的全球负担仍然很高。为了到2050年消除结核病这一公共卫生问题，所有负责各方需要共同努力，加强全球抗结核病药物管道，并支持开发新的抗结核病药物方案。
Drugs for tuberculosis are inadequate to address the many inherent and emerging challenges of treatment. In the past decade, ten compounds have progressed into the clinical development pipeline, including six new compounds specifically developed for tuberculosis. Despite this progress, the global drug pipeline for tuberculosis is still insufficient to address the unmet needs of treatment. Additional and sustainable efforts, and funding are needed to further improve the pipeline. The key challenges in the development of new treatments are the needs for novel drug combinations, new trial designs, studies in paediatric populations, increased clinical trial capacity, clear regulatory guidelines, and biomarkers for prediction of long-term outcome. Despite substantial progress in efforts to control tuberculosis, the global burden of this disease remains high. To eliminate tuberculosis as a public health concern by 2050, all responsible parties need to work together to strengthen the global antituberculosis drug pipeline and support the development of new antituberculosis drug regimens.